**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 81998

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Effect of modified ShengYangYiwei decoction on painless gastroscopy and gastrointestinal and immune function in gastric cancer patients**

Mi SC *et al*. Traditional Chinese medicine optimizes painless gastroscopy

Sui-Cai Mi, Ling-Yan Wu, Zheng-Jin Xu, Li-Yan Zheng, Jian-Wen Luo

**Sui-Cai Mi, Jian-Wen Luo,** Department of Oncology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, Fujian Province, China

**Ling-Yan Wu, Zheng-Jin Xu,** Department of Nephropathy, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, Fujian Province, China

**Li-Yan Zheng,** Department of Anesthesiology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, Fujian Province, China

**Author contributions:** Mi SC, Wu LY, and Zheng LY performed the research; Mi SC, and the research; Mi SC designed the research study; Luo JW and Xu ZJ contributed collection and assembly of data; Zheng LY and Wu LY analysed the data; Zheng LY and Wu LY analysed the data; Mi SC and Wu LY wrote the pape.

**Supported by** Xiamen Municipal Science and Technology Bureau Municipal Medical and Health Guidance Project, No. 3502Z20224ZD1169; Joint project of Natural Science Foundation of Xiamen Municipal Bureau of Science and Technology, No. 3502Z20227368; and The Sixth Batch of Chinese Medicine Reserve Talent Training Project in Xiamen (Xiamen Municipal Health Commission Traditional Chinese Medicine), No. [2022] No. 136.

**Corresponding author: Ling-Yan Wu, MMed, Deputy Director,** Department of Nephropathy, Xiamen Hospital of Traditional Chinese Medicine, No. 1739 Xianyue Road, Huli District, Xiamen 361000, Fujian Province, China. 418569189@qq.com

**Received:** December 6, 2022

**Revised:** March 7, 2023

**Accepted:** April 12, 2023

**Published online:** May 16, 2023

**Abstract**

BACKGROUND

Painless gastroenteroscopy is a widely developed diagnostic and treatment technology in clinical practice. It is of great significance in the clinical diagnosis, treatment, follow-up review and other aspects of gastric cancer patients. The application of anesthesia techniques during manipulation can be effective in reducing patient fear and discomfort. In clinical work, the adverse drug reactions of anesthesia regimens and the risk of serious adverse drug reactions are increased with the increase in propofol application dose application dose; the application of opioid drugs often causes gastrointestinal reactions, such as nausea, vomiting and delayed gastrointestinal function recovery, after examination. These adverse effects can seriously affect the quality of life of patients.

AIM

To observe the effect of modified ShengYangYiwei decoction on gastrointestinal function, related complications and immune function in patients with gastric cancer during and after painless gastroscopy.

METHODS

A total of 106 patients with gastric cancer, who were selected from January 2022 to September 2022 in Xiamen Traditional Chinese Medicine Hospital for painless gastroscopy, were randomly divided into a treatment group (*n* = 56) and a control group (*n* = 50). Before the examination, all patients fasted for 8 h, provided their health education, and confirmed if there were contraindications to anesthesia and gastroscopy. During the examination, the patients were placed in the left decubitus position, the patients were given oxygen through a nasal catheter (6 L/min), the welling needle was opened for the venous channel, and a multifunction detector was connected for monitoring electrocardiogram, oxygen saturation, blood pressure, *etc.* Naporphl and propofol propofol protocols were used for routine anesthesia. Before anesthesia administration, the patients underwent several deep breathing exercises, received intravenous nalbuphine [0.nalbuphine (0.025 mg/kg)], followed by intravenous propofol [1.propofol (1.5 mg/kg)] until the palpebral reflex disappeared, and after no response, gastroscopy was performed. If palpebral reflex disappeared, and after no response, gastroscopy was performed. If any patient developed movement, frowning, or hemodynamic changes during the operation (heart rate changes during the operation (heart rate increased to > 20 beats/min, systolic blood pressure increased to > 20% of the base value), additional propofol [0.propofol (0.5 mg/kg)] was added until the patient was sedated again. The patients in the treatment group began to take the preventive intervention of Modified ShengYangYiwei decoction one week before the examination, while the patients in the control group received routine gastrointestinal endoscopy. The patients in the two groups were examined by conventional painless gastroscopy, and the characteristics of the painless gastroscopies of the patients in the two groups were recorded and compared. These characteristics included the total dosage of propofol during the examination, the incidence of complications during the operation, the time of patients' awakening, the time of independent activities, and the gastrointestinal function of the patients after examination, such as the incidence of reactions such as malignant vomiting, abdominal distension and abdominal pain, as well as the differences in the levels of various immunological indicators and inflammatory factors before anesthesia induction (T0), after conscious extubation (T1) and 24 h after surgery (T2).

RESULTS

There was no difference in the patients’ general information, American Society of Anesthesiologist classification or operation time between the two groups before treatment. In terms of painless gastroscopy, the total dosage of propofol in the treatment group was lower than that in the control group (*P* < 0.05), and the time of awakening and autonomous activity was significantly faster than that in the control group (*P* < 0.05). During the examination, the incidence of hypoxemia, hypotension and hiccups in the treatment group was significantly lower than that in the control group (*P* < 0.01). In terms of gastrointestinal function, the incidences of nausea, vomiting, abdominal distension and abdominal pain in the treatment group after examination were significantly lower than those in the control group (*P* < 0.01). In terms of immune function, in both groups, the number of CD4+ and CD8+ cells decreased significantly (*P* < 0.05), and the number of natural killer cells increased significantly (*P* < 0.05) at T1 and T2, compared with T0. The number of CD4+ and CD8+ cells in the treatment group at the T1 and T2 time points was higher than that in the control group (*P* < 0.05), while the number of natural killer cells was lower than that in the control group (*P* < 0.05). In terms of inflammatory factors, compared with T0, the levels of interleukin (IL) -6 and tumor necrosis factor-alpha in patients in the two groups at T1 and T2 increased significantly and then decreased (*P* < 0.05). The level of IL-6 at T1 and T2 in the treatment group was lower than that in the control group (*P* < 0.05).

CONCLUSION

The preoperative use of modified ShengYangYiwei decoction can optimize the anesthesia program during painless gastroscopy, improve the gastrointestinal function of patients after the operation, reduce the occurrence of examination-related complications.

**Key Words:** Modified ShengyangYiwei decoction; Gastric cancer patients; Painless gastroscope; Gastrointestinal function

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Mi SC, Wu LY, Xu ZJ, Zheng LY, Luo JW. Effect of modified ShengYangYiwei decoction on painless gastroscopy and gastrointestinal and immune function in gastric cancer patients. *World J Gastrointest Endosc* 2023; 15(5): 376-385

**URL:** <https://www.wjgnet.com/1948-5190/full/v15/i5/376.htm>

**DOI:** https://dx.doi.org/10.4253/wjge.v15.i5.376

**Core Tip:** The preoperative use of modified ShengyangYiwei decoction can optimize the anesthesia program during painless gastroscopy, significantly reduce the total dose of propofol during the examination without affecting the quality of the examination, thereby shortening the time of awakening and independent activity, and reducing the occurrence of hypoxemia, hypotension and hiccup during the examination; It improves the gastrointestinal function of patients after operation, reduces the incidence of nausea, vomiting, abdominal distension, abdominal pain and other complications of patients, reduces the inhibition of opioids on the immune system of the body, reduces the inflammatory reaction of patients, is beneficial to the development of painless gastroscopy for gastric cancer patients in clinical practice, reduces the occurrence of examination related complications, and improves the compliance and tolerance of treatment.

**INTRODUCTION**

Painless gastroenteroscopy is a widely developed diagnostic and treatment technology in clinical practice. It is of great significance in the clinical diagnosis, treatment, follow-up review and other aspects of gastric cancer patients. It can also be used to evaluate patients with reflux esophagitis, esophageal cancer, gastroduodenal ulcer, *etc*[1,2]. The application of anesthesia techniques during manipulation can be effective in reducing patient fear and discomfort[3]. Propofol combined with opioids are common clinical drugs for painless endoscopic sedation and anesthetics[4]. On the one hand, in clinical work, the adverse drug reactions and the risk of anesthesia regimens are increased with the increase in propofol application dose; on the other hand, the application of opioid drugs often causes gastrointestinal reactions, such as nausea, vomiting and delayed gastrointestinal function recovery, after examination. These adverse effects can seriously affect the quality of life of patients.

Modified ShengYangYiwei decoction is related to Li Dongyuan's theory, which has the effect of replenishing Qi and rising Yang, clearing heat and detoxification, and removing dampness and turbidity. It has achieved fine effect in the field of digestive endoscopy[5]. Therefore, this study observed the treatment interventions of gastric cancer patients and observed the impact on patients' gastrointestinal function, related complications and immune function during and after painless gastroscopy.

**MATERIALS AND METHODS**

***Clinical data***

This study was approved by the Medical Ethics Committee of the Xiamen Hospital of Traditional Chinese Medicine (2022-K028-01), and informed consent was signed by all patients.

**The inclusion criteria were as follows:** (1) Aged 18–65 years, with a body mass index index of 28 kg/m2; (2) American Society of Anesthesiologist grade of I-II; and (3) no contraindications for gastroscopy.

**The exclusion criteria were as follows:** (1) Major cardiovascular and cerebrovascular diseases and failure to cooperate with the examination; (2) gravida; (3) propofol, opioid allergy or intolerance; and (4) psychotropic drugs use or abnormal coagulation function before surgery.

**General Information:** A total of 106 gastric cancer patients from January 2022 to September 2022 who were selected for painless gastroscopy in Xiamen Hospital of Traditional Chinese Medicine, were divided into a treatment group (*n* = 56) and a control group (*n* = 50) by the random number table method. The purpose of painless gastroscopy for the two groups of patients is to conduct health screening and timely diagnosis. The general data between the two groups were not significantly different (*P* > 0.05) and were comparable Table 1.

***Treatment methods***

Before the examination, all patients fasted for 8 h, provided their health education, and confirmed if there were contraindications to anesthesia and gastroscopy. During the examination, the patients were placed in the left decubitus position, the patients were given oxygen through a nasal catheter (6 L/min), the welling needle was opened for the venous channel, and a multifunction detector was connected for monitoring electrocardiogram, oxygen saturation, blood pressure, *etc.*

For the control group, the protocols followed the Expert Consensus on Sedation and Anesthesia in the Diagnosis and Treatment of Digestive Endoscopy in China[6]. Naporphl and propofol protocols were used for routine anesthesia. Before anesthesia administration, the patients underwent several deep breathing exercises, received intravenous nalbuphine (0.025 mg/kg), followed by intravenous propofol (1.5 mg/kg) until the palpebral reflex disappeared, and after no response, gastroscopy was performed. If any patient developed movement, frowning, or hemodynamic changes during the operation (heart rate increased to > 20 beats/min, systolic blood pressure increased to > 20% of the base value), additional propofol (0.5 mg/kg) was added until the patient was sedated again.

The patients in the treatment group began oral Modified ShengYangYiwei decoction one week before gastroscopy, with one dose a day, compared with the control group. The Modified ShengYangYiwei decoction specific composition is "30 g of ginseng, 9 g of atractylodes macrocephala, 9 g of poria, 60 g of astragalus, 15 g of white peony, 30 g of pinellia ternata, 6 g of rhizoma coptidis, 9 g of rhizoma alismatis, 12 g of dried tangerine peel, 10 g of magnolia officinalis, 9 g of rhizoma Notopterygii, 9 g of angelica pubescens, 9 g of fangfeng, 9 g of bupleurum chinense, 5 g of ginger, 6 g of jujube (denuded), 6 g of cohosh, 9 g of kudzu, 9 g of pueraria lobata, 15 g of Shijian Chuan, 12 g of divine koji, and 6 g of raw licorice". Boil and concentrate the drug with 500 mL water to 200 mL, twice in total. Then divide into two portions and take orally after breakfast and dinner.

Observation indicators: The painless gastroscopy data was recorded (1) in the two groups, and these data included the operation time (from the beginning to the end of the examination), awakening time (From the end of the examination to the time when the patient can correctly answer questions such as his name and birthday), autonomous walking time (from the end of the examination to when the patient can go to bed and walk steadily), the total dose of propofol during the examination; (2) the incidence of complications (hypoxemia, hypotension, hiccup, *etc.*) during anesthesia; (3) gastrointestinal reactions (nausea, vomiting, abdominal distension, abdominal pain, *etc.*) occurred after examination; and (4) T-cell subsets and inflammatory levels at different times. T-cell subpopulation was detected by flow cytometry, and the level of inflammatory factors was detected by biochemical immunoassay.

***Statistical methods***

SPSS 22.0 software was used for data analysis. The measurement data are expressed as (mean ± SD), after verifying the normal distribution of indicators in each group and *t* tests were utilized. The counting data are expressed as [*n* (%)] using *χ*2 analysis. The *F* test for analysis of variance was used for comparisons among multiple groups, and the difference was considered statistically significant if *P* < 0.05.

**RESULTS**

***Comparison of gastroscopy between the two groups***

The operation time of gastroscopy was 4-6 min, without any obvious difference (*P* > 0.05); the awakening time of the treatment group were significantly faster than the control group (*P* < 0.05); the Self-ambulation time of the treatment group were significantly faster than the control group (*P* < 0.05) and for the treatment, the total dose of propofol was was significantly lower than the control group (*P* < 0.01), shown in Table 2.

***Comparison of complication occurrence during the examination between the two groups***

In the two groups, hypoxemia, hypotension and hiccups were common during painless gastroscopy, and the incidences of these complications were lower than that in the control group. There were significant differences (*P* < 0.05), as shown in Table 3.

***Comparison of gastrointestinal function after completing the examination in the two groups***

After the end of the examination, as shown in Table 4, the incidence of abdominal distension, nausea, abdominal pain, and vomiting in the treatment group was significantly lower than that in the control group (*P* < 0.05).

***Immune cell numerical values at different times***

At T0, there was no significant difference in the CD4+, CD8+, and natural killer (NK) cell numbers between the two groups (*P* > 0.05). After examination, the CD4+ and CD8+ cells and NK cells at T1 and T2 were significantly decreased (*P* < 0.05). Comparing the two groups, the CD4+ and CD8+ cells at T1 and T2 were higher than that in the control group(*P* < 0.0 5); and NK cells at T1 and T2 were lower than that in the control group (*P* < 0.05) Table 5.

***Comparison of inflammatory factors at different times***

At the T0 time point, the interleukin (IL) -6 and tumor necrosis factor-alpha (TNF-α) levels were comparable (*P* > 0.05); after the examination operation, IL-6 and TNF-α at T1 and T2 were significantly higher than before the examination (*P* < 0.05). With further comparisons between the two groups, IL-6 and TNF-α at T1 and T2 were significantly lower than the control group (*P* < 0.05), as shown in Table 6.

**DISCUSSION**

Painless gastroscopy is gradually becoming a widely accepted examination means in the clinical diagnosis and treatment of gastric cancer, premalignant diseases, tissue mucosal lesions and other diseases[7,8]. The use of propofol in combination with naborphine painless treatment has become a safer anesthesia regimen commonly used in clinical practice[9-11]. However, patients with gastric cancer have a poor physique and are often more prone to anesthesia-related adverse reactions and gastrointestinal-related complications during examination[12]. At present, combining other methods to further reduce the impact of examination on gastrointestinal function in gastric cancer patients has become an area of exploration in current research.

We have summarized the experience in clinical practice for a long time and formed a special treatment agreement of "Modified Shengyang Yiwei Decoction". In this prescription, the whole recipe can replenish the middle and disperse the hair and recover the hair so that the positive qi can be sufficient, and the yang qi can be generated. It can improve the local inflammatory response of the gastric mucosa, regulate the imbalance between cell proliferation and apoptosis, repair the local blood circulation of the gastric mucosa, and improve the pathological state of the gastric mucosa[13]. Xu *et al*[14] found that Shengyangyi gastric soup could inhibit the expression of nuclear factor-kappaB (NF-κB), B cell lymphoma-2 (Bcl-2), c-myc, and Cyclin-D1 in the gastric mucosa tissue of precancerous lesions of gastric cancer (PLGC) rats and regulate gastric mucosal cell apoptosis, thus improving the gastrointestinal function of patients. Zeng *et al*[15] found that it inhibited the conduction of the NF-κB/signal transducer and activator of transcription 3 signaling pathway, with significant upregulation of target gene p21 expression, downregulation of Bcl-2 and c-myc, and reduced expression of the inflammatory factors mediated by it. Zhao *et al*[16] found that the application of Shengyangyi gastric soup, and the scattered knot method can promote the wound healing of hyperplastic gastric polyps after gastroscopy and may reduce the degree of their precancerous lesions by reducing the expression of Bcl-2, which has positive significance for the prevention and treatment of hyperplastic polyps and their precancerous lesions. Wu *et al*[17] also found that the intervention treatment of ShengYangYiwei decoction on PLGC rats can upregulate the expression of p16 and wild-type p53 protein, promote local microvascular proliferation, and improve the structure of patients' gastrointestinal mucosa, and they confirmed that ShengYangYiwei decoction can effectively block the disease progression of precancerous lesions of gastric cancer. This shows that Modified ShengYangYiwei Decoction can improve the repair and reproduction of gastric mucosal cells, regulate cell apoptosis, and even inhibit the malignant proliferation of gastric parietal cells. According to the literature, Modified ShengYangYiwei decoction can increase cerebral blood flow, accelerate the passage of propofol through the blood brain barrier, and thus reduce the induced dose of propofol[18,19]. In this study, the operation time of the two groups of patients undergoing gastroscopy lasted approximately 4 minutes. However, in the treatment group, the total dose of propofol used by patients is less, and after examination, the recovery time and independent walking time of patients were significantly shorter than those in the control group. It may be relatde to that the treatment with ShengYangYiwei Decoction reduced the dose of propofol or increased in β-endorphin secretion[20], which deserves further study.

On the other hand, during painless gastroscopy, especially in the application of large propofol doses, the risk of inducing respiratory suppression and blood pressure fluctuations is high, and these are the most common cardiopulmonary complication of painless gastroscopy[21]. In our study, the incidence of hypoxemia and hypotension in the Modified ShengYangYiwei decoction treatment group was significantly lower than that in the control group, and this medication is likely associated with reducing the dose of propofol. Thus, the incidence of respiratory depression and hypotension was reduced. Moreover, the most common complication after painless gastroscopy is the gastrointestinal reaction, and patients often have nausea, vomiting, abdominal distension and abdominal pain within several hours or even a few days after the examination[22,23]. Our study suggested that hiccups, nausea, vomiting, abdominal distension, and abdominal pain occurred. The rate was significantly lower in the treatment group than that in the control group (*P* < 0.05). After further querying the literature, treatment with Modified ShengYangYiwei Decoction can reduce the activity and reduce sympathetic nerve stimulation. The decrease in the vagus nerve stimulation then relieves gastrointestinal spasms to relieve nausea and vomiting and reduce the occurrence of abdominal distension and abdominal pain[24,25]. The degree of pain of the patients after gastroscopy was slight, and the satisfaction of the surgeons and patients with painless gastroscopy was relatively high in both groups, which also suggested that the patients and the surgeons both recognized the anesthesia method of this examination, which was worthy of promotion and research.

Moreover, the inhibition of cell-mediated immunity (mainly NK cells and T lymphocytes) and excessive proinflammatory responses are key features of perioperative cytokine cascade activation[26,27]. The results of the present study show that, in contrast to the T0, T1, and T2 time stages, C. NK cells increased significantly in both groups, which was associated with the postoperative inflammatory nature. The number of CD4+ and CD8+ cells decreased significantly in both groups, illustrating that surgery and anesthesia induced a stress response in the patient's body, producing significant immunosuppression. However, the values of CD4+ and CD8+ cells in the treatment group at T1 and T2 were higher than that in the control group, which indicates that the cellular immunity was less suppressed in the treatment group, and this is beneficial in reducing the postoperative complications in the patients. The IL-6 and TNF-α expression levels were further analyzed in both groups. IL-6 and TNF-α are released into the body with proinflammatory cytokines and can inhibit the effects of NK cells, CD4+ Th1-type cells and CD8+ T cells, which are associated with cancer cell proliferation and survival. This trial showed that the expression levels of IL-6 and TNF-α at T1 and T2 were significantly lower than those in the control group, preventing the excessive inflammatory response in the body, and the potential antitumor effect is also worth further study.

**CONCLUSION**

In summary, the preoperative use of modified ShengYangYiwei decoction can optimize the anesthesia program during painless gastroscopy and can significantly reduce the total dose of propofol during the inspection process without affecting the quality of inspection operation, thus shortening the time of awakening and independent activity and reducing the occurrence of hypoxemia, hypotension and hiccups during the inspection process. It improves the gastrointestinal function of patients after operation, reduces the incidence of nausea, vomiting, abdominal distension, abdominal pain and other complications of patients, reduces the inhibition of opioids on the immune system of the body, reduces the inflammatory reaction of patients, is beneficial to the development of painless gastroscopy for gastric cancer patients in clinical practice, reduces the occurrence of examination-related complications, and improves the compliance and tolerance of treatment. It is safe and feasible.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastroscopy is of great significance in the clinical diagnosis, treatment, follow-up review and other aspects of gastric cancer patients, it can also be used to evaluate patients with reflux esophagitis, esophageal cancer, gastroduodenal ulcer, *etc. I*n clinical practice, painless gastroscopy is a widely accepted examination means. The use of propofol in combination with naborphine painless treatment has become a safer anesthesia regimen commonly used in clinical practice. However, patients with gastric cancer have a poor physique and are often more prone to anesthesia-related adverse reactions and gastrointestinal-related complications during examination. At present, combining other methods to further reduce the impact of examination on gastrointestinal function in gastric cancer patients has become an area of exploration in current research.

***Research motivation***

In order to explore a new intervention plan to optimize the anesthesia drug plan for painless gastroscopy and reduce the anesthesia related complications and postoperative discomfort of patients during the examination.

***Research objectives***

Modified ShengYangYiwei decoction is related to Li Dongyuan's theory, which has the effect of replenishing Qi and rising Yang, clearing heat and detoxification, and removing dampness and turbidity. It has gradually achieved fine effects in the field of digestive endoscopy. Therefore, this study observed the treatment interventions of gastric cancer patients and observed the impact on patients' gastrointestinal function, related complications and immune function during and after painless gastroscopy.

***Research methods***

A total of 106 gastric cancer patients from January 2022 to September 2022 who were selected for painless gastroscopy in Xiamen Hospital of Traditional Chinese Medicine, were divided into a treatment group (*n* = 56) and a control group (*n* = 50) by the random number table method. Before the examination, all patients fasted for 8 h, provided their health education, and confirmed if there were contraindications to anesthesia and gastroscopy. During the examination, for the control group, the protocols followed the Expert Consensus on Sedation and Anesthesia in the Diagnosis and Treatment of Digestive Endoscopy in China. The patients in the treatment group began oral Modified ShengYangYiwei decoction one week before gastroscopy, with one dose a day, compared with the control group.

***Research results***

There was no difference in the patients’ general information, American Society of Anesthesiologist classification or operation time between the two groups. In terms of painless gastroscopy, the total dosage of propofol in the treatment group was lower than that in the control group (*P* < 0.05), and the time of awakening and autonomous activity was faster than that in the control group (*P* < 0.05). During the examination, the incidence of hypoxemia, hypotension and hiccups in the treatment group was lower than that in the control group (*P* < 0.01). After examination, the incidences of nausea, vomiting, abdominal distension and abdominal pain were lower than those in the control group (*P* < 0.01). In terms of immune function, in both groups, the number of CD4+ and CD8+ cells decreased significantly (*P* < 0.05), and the number of natural killer (NK) cells increased (*P* < 0.05) at T1 and T2, compared with T0. The number of CD4+ and CD8+ cells in the treatment group at the T1 and T2 time points was higher, while the number of NK cells was lower than that in the control group (*P* < 0.05). In terms of inflammatory factors, the level of IL-6 at T1 and T2 in the treatment group was lower than that in the control group (*P* < 0.05).

***Research conclusions***

The preoperative use of Modified ShengYangYiwei decoction can optimize the anesthesia program during painless gastroscopy, improve the gastrointestinal function of patients after the operation, reduce the occurrence of examination-related complications.

***Research perspectives***

At present, combining other methods to further reduce the impact of examination on gastrointestinal function in gastric cancer patients has become an area of exploration in current research. The preoperative use of Modified ShengYangYiwei decoction can improve the gastrointestinal function of patients after the operation. This trial showed that the expression levels of IL-6 and TNF-α at T1 and T2 were significantly lower than those in the control group, preventing the excessive inflammatory response in the body, and the potential antitumor effect is also worth further study.

**REFERENCES**

1 **Men F**, Wei L, Liu B, Wu F, Liu J, Guo N, Niu Q. Comparison of the safety of the application of painless gastroscopy and ordinary gastroscopy in chronic hypertension patients combined with early gastric cancer. *Oncol Lett* 2018; **15**: 3558-3561 [PMID: 29467876 DOI: 10.3892/ol.2018.7737]

2 **Liang H**, Hou Y, Sun L, Li Q, Wei H, Feng Y. Supraglottic jet oxygenation and ventilation for obese patients under intravenous anesthesia during hysteroscopy: a randomized controlled clinical trial. *BMC Anesthesiol* 2019; **19**: 151 [PMID: 31409366 DOI: 10.1186/s12871-019-0821-8]

3 **Shao LJ**, Hong FX, Liu FK, Wan L, Xue FS. Prospective, randomized comparison of two supplemental oxygen methods during gastroscopy with propofol mono-sedation in obese patients. *World J Clin Cases* 2021; **9**: 5479-5489 [PMID: 34307602 DOI: 10.12998/wjcc.v9.i20.5479]

4 **American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists**. Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology* 2002; **96**: 1004-1017 [PMID: 11964611 DOI: 10.1097/00000542-200204000-00031]

5 **Xiong M**, Luo H, Zhu W, Shen T. Shengyang Yiwei Decoction for the treatment of chronic gastritis: A protocol for a systematic review and meta-analysis. *Medicine (Baltimore)* 2020; **99**: e22869 [PMID: 33120827 DOI: 10.1097/MD.0000000000022869]

6 **Gralnek IM**, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, Laursen SB, Radaelli F, Papanikolaou IS, Cúrdia Gonçalves T, Dinis-Ribeiro M, Awadie H, Braun G, de Groot N, Udd M, Sanchez-Yague A, Neeman Z, van Hooft JE. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. *Endoscopy* 2021; **53**: 300-332 [PMID: 33567467 DOI: 10.1055/a-1369-5274]

7 **Du Y**, Bai Y, Xie P, Fang J, Wang X, Hou X, Tian D, Wang C, Liu Y, Sha W, Wang B, Li Y, Zhang G, Li Y, Shi R, Xu J, Li Y, Huang M, Han S, Liu J, Ren X, Xie P, Wang Z, Cui L, Sheng J, Luo H, Wang Z, Zhao X, Dai N, Nie Y, Zou Y, Xia B, Fan Z, Chen Z, Lin S, Li ZS; Chinese Chronic Gastritis Research group. Chronic gastritis in China: a national multi-center survey. *BMC Gastroenterol* 2014; **14**: 21 [PMID: 24502423 DOI: 10.1186/1471-230X-14-21]

8 **Pimentel-Nunes P**, Libânio D, Lage J, Abrantes D, Coimbra M, Esposito G, Hormozdi D, Pepper M, Drasovean S, White JR, Dobru D, Buxbaum J, Ragunath K, Annibale B, Dinis-Ribeiro M. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. *Endoscopy* 2016; **48**: 723-730 [PMID: 27280384 DOI: 10.1055/s-0042-108435]

9 **Hinkelbein J,** Lamperti M, Akeson J, Santos J, Costa J, De Robertis E, Longrois D, Novak-Jankovic V, Petrini F, Struys MMRF, Veyckemans F, Fuchs-Buder T, Fitzgerald R. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. *Eur J Anaesthesiol* 2018; **35:** 6-24 [PMID: 28877145 DOI: 10.1097/EJA.0000000000000683]

10 **McQuaid KR**, Laine L. A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures. *Gastrointest Endosc* 2008; **67**: 910-923 [PMID: 18440381 DOI: 10.1016/j.gie.2007.12.046]

11 **Qadeer MA**, Vargo JJ, Khandwala F, Lopez R, Zuccaro G. Propofol versus traditional sedative agents for gastrointestinal endoscopy: a meta-analysis. *Clin Gastroenterol Hepatol* 2005; **3**: 1049-1056 [PMID: 16271333 DOI: 10.1016/s1542-3565(05)00742-1]

12 **Xie S,** Ma W, Guo Q, Liu J, Li W, McLeod HL, He Y. The pharmacogenetics of medications used in general anesthesia. *Pharmacogenomics* 2018; **19:** 285-298 [PMID: 29318929 DOI: 10.2217/pgs-2017-0168]

13 **Lu Y**, Liu H, Yang K, Mao Y, Meng L, Yang L, Ouyang G, Liu W. A comprehensive update: gastrointestinal microflora, gastric cancer and gastric premalignant condition, and intervention by traditional Chinese medicine. *J Zhejiang Univ Sci B* 2022; **23**: 1-18 [PMID: 35029085 DOI: 10.1631/jzus.B2100182]

14 **Xu J**, Shen W, Pei B, Wang X, Sun D, Li Y, Xiu L, Liu X, Lu Y, Zhang X, Yue X. Xiao Tan He Wei Decoction reverses MNNG-induced precancerous lesions of gastric carcinoma in vivo and vitro: Regulation of apoptosis through NF-κB pathway. *Biomed Pharmacother* 2018; **108**: 95-102 [PMID: 30218863 DOI: 10.1016/j.biopha.2018.09.012]

15 **Zeng J**, Yan R, Pan H, You F, Cai T, Liu W, Zheng C, Zhao Z, Gong D, Chen L, Zhang Y. Weipixiao attenuate early angiogenesis in rats with gastric precancerous lesions. *BMC Complement Altern Med* 2018; **18**: 250 [PMID: 30200948 DOI: 10.1186/s12906-018-2309-3]

16 **Zhao M,** Jiang Y, Chen Z, Fan Z, Jiang Y. Traditional Chinese medicine for Helicobacter pylori infection: A protocol for a systematic review and meta-analysis. *Medicine (Baltimore)* 2021; **100:** e24282. [PMID: 33546052 DOI: 10.1097/MD.0000000000024282]

17 **Wu H**, Miao X, Liu Y, Zhang S, Li C, Hao J. Clinical Efficacy of Modified Yiwei Shengyang Decoction Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Gastric Cancer and Its Effect on Tumor Marker Levels. *Evid Based Complement Alternat Med* 2022; **2022**: 6234032 [PMID: 35571732 DOI: 10.1155/2022/6234032]

18 **Li Y**, Li X, Tan Z. An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis. *Helicobacter* 2021; **26:** e12799.5 [PMID: 33765344 DOI: 10.1111/hel.12799]

19 **Luo H,** Li Q, Flower A, Lewith G, Liu J. Comparison of effectiveness and safety between granules and decoction of Chinese herbal medicine: a systematic review of randomized clinical trials. *J Ethnopharmacol* 2012; **140:** 555-567 [PMID: 22343092 DOI: 10.1016/j.jep.2012.01.031]

20 **Qadeer MA**, Lopez AR, Dumot JA, Vargo JJ. Hypoxemia during moderate sedation for gastrointestinal endoscopy: causes and associations. *Digestion* 2011; **84**: 37-45 [PMID: 21304242 DOI: 10.1159/000321621]

21 **Zhan Y**, Liang S, Yang Z, Luo Q, Li S, Li J, Liang Z, Li Y. Efficacy and safety of subanesthetic doses of esketamine combined with propofol in painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial. *BMC Gastroenterol* 2022; **22**: 391 [PMID: 35987996 DOI: 10.1186/s12876-022-02467-8]

22 **Skovlund E**, Bretthauer M, Grotmol T, Larsen IK, Hoff G. Sensitivity of pain rating scales in an endoscopy trial. *Clin J Pain* 2005; **21**: 292-296 [PMID: 15951645 DOI: 10.1097/01.ajp.0000110636.14355.3e]

23 **Cai T**, Zhang C, Zhao Z, Li S, Cai H, Chen X, Cai D, Liu W, Yan Y, Xie K, Pan H, Zeng X. The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats. *Biomed Pharmacother* 2018; **104**: 291-299 [PMID: 29775897 DOI: 10.1016/j.biopha.2018.04.013]

24 **Porter SB**. Perioperative ketamine for acute analgesia and beyond. *Rom J Anaesth Intensive Care* 2019; **26**: 67-73 [PMID: 31111098 DOI: 10.2478/rjaic-2019-0010]

25 **Riganti C**, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D, Bosia A. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. *Br J Pharmacol* 2009; **156**: 1054-1066 [PMID: 19298255 DOI: 10.1111/j.1476-5381.2009.00117.x]

26 **Ni Choileain N**, Redmond HP. Cell response to surgery. *Arch Surg* 2006; **141**: 1132-1140 [PMID: 17116807 DOI: 10.1001/archsurg.141.11.1132]

27 **Horowitz M**, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. *Nat Rev Clin Oncol* 2015; **12**: 213-226 [PMID: 25601442 DOI: 10.1038/nrclinonc.2014.224]

**Footnotes**

**Institutional review board statement:** This study was approved by the Institutional Review Board of Xiamen Hospital of Traditional Chinese Medicine (approval No: 20211129).

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this study.

**Conflict-of-interest statement:** All the authors declare that they have no conflict of interest with this work.

**Data sharing statement:** All data during the study period are included in the public database.

**STROBE statement:** he authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 6, 2022

**First decision:** February 28, 2023

**Article in press:** April 12, 2023

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Senchukova M, Russia; Uygur FA, Turkey **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Cai YX

**Table 1 Comparison of the general data between the two patient groups**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Sex** | | **ASA classify** | | **Median age (age)** |
| **Man** | **Woman** | **I level** | **II level** |
| Treatment group (*n* = 56) | 32 | 24 | 44 | 12 | 36 (20-66) |
| Control group (*n* = 50) | 26 | 24 | 42 | 8 | 41 (19-61) |
| *χ*2/*t* value | 0.564 | | 0.218 | | 0.461 |
| *P* value | > 0.05 | | > 0.05 | | > 0.05 |

ASA: American Society of Anesthesiologist.

**Table 2 Comparison of gastroscopy in the two groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | **Operation time (min)** | **Wakeup time (min)** | **Self-ambulation time (min)** | **Total dose of propofol (mg)** |
| Treatment group (*n* = 56) | 4.43 ± 2.41 | 3.36 ± 0.27 | 6.02 ± 0.26 | 115.36 ± 8.17 |
| Control group (*n* = 50) | 4.35 ± 2.33 | 6.71 ± 0.34 | 7.68 ± 0.61 | 146.21 ± 10.17 |
| *t* value | 0.497 | 4.215 | 3.234 | 3.213 |
| *P* value | > 0.05 | < 0.01 | < 0.05 | < 0.01 |

**Table 3 Comparison of complications between the two groups during anaesthesia, *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Hypoxemia** | **Hypotension** | **Hiccup** | ***F* value** | ***P* value** |
| Treatment group (*n* = 56) | 6 (10.71) | 22 (10.54) | 3 (5.36) | 17.19 | < 0.05 |
| Control group (*n* = 50) | 10 (20) | 15 (30.00) | 6 (12.00) |  |  |

**Table 4 Comparison of gastrointestinal reactions between the two groups after examination, *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Nausea** | **Vomiting** | **Abdominal distension** | **Abdominal pain** | ***F* value** | ***P* value** |
| Treatment group (*n* = 56) | 10 (17.86) | 4 (7.14) | 8 (14.29) | 4 (7.14) | 11.78 | < 0.05 |
| Control group (*n* = 50) | 13 (26.00) | 8 (16.00 | 13 (26.00) | 6 (12.00) |  |  |

**Table 5 Comparison of immune cell values in T0, T1 and T2 between the two groups (%), mean ± SD**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **CD4+** | | | **CD8+** | | | **NK cell** | | |
| **T0** | **T1** | **T2** | **T0** | **T1** | **T2** | **T0** | **T1** | **T2** |
| Treatment group (*n* = 56) | 40.65 ± 6.73 | 37.16 ± 5.78a,b | 33.75 ± 5.36a,c | 25.91 ± 6.25 | 22.35 ± 5.49a,b | 21.03 ± 4.35a,c | 14.54 ± 1.34 | 16.61 ± 1.80a,b | 20.74 ± 1.77a,c |
| Control group (*n* = 50) | 41.56 ± 7.19 | 35.19 ± 6.31a | 29.09 ± 5.63a | 26.15 ± 5.58 | 21.11 ± 4.74a | 18.49 ± 4.56a | 14.40 ± 1.34 | 21.79 ± 1.45a | 26.81 ± 1.39a |

a*P* < 0.05 *vs* T0.

b*P* < 0.05 *vs* controls with T1.

c*P* < 0.05 *vs* controls with T2. NK: Natural killer.

**Table 6 Comparison of inflammatory indicators in T0, T1 and T2 between the two groups, mean ± SD**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | **IL-6 (pg/mL)** | | | **TNF-α (ng/L )** | | |
| **T0** | **T1** | **T2** | **T0** | **T1** | **T2** |
| Treatment group (*n* = 56) | 50.18 ± 9.05 | 109.58 ± 14.95a,b | 70.81 ± 9.50a,c | 9.63 ± 2.17 | 12.53 ± 2.27a,b | 10.48 ± 3.48a,c |
| Control group ( *n* = 50) | 49.06 ± 9.41 | 128.64 ± 18.61a | 89.61 ± 9.41a | 9.70 ± 1.99 | 16.28 ± 3.74a | 14.62 ± 3.57a |

a*P* < 0.05 *versus* T0.

b*P* < 0.05 compared to controls with T1.

c*P* < 0.05 compared to controls with T2. TNF-α: Tumor necrosis factor-alpha.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**